IVIg for relapsing-remitting multiple sclerosis: Promises and uncertainties

Trends in Pharmacological Sciences

Volumn 36, Issue 7, 2015, Pages 419-421

  Bayry, Jagadeesh ^a,b,c,d,e   Hartung, Hans Peter ^f   Kaveri, Srini V ^a,b,c,d,e  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

autoimmunity; biomarkers; immunotherapy; inflammation; IVIg; multiple sclerosis

Indexed keywords

IMMUNOGLOBULIN; PLACEBO; IMMUNOLOGIC FACTOR;

ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TH1 CELL; TH17 CELL; UNCERTAINTY; DRUG ADMINISTRATION; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; UNCERTAINTY;

EID: 84932194321     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.04.012     Document Type: Short Survey

References (12)

1. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
2. M. Buttmann Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders Trends Pharmacol. Sci. 34 2013 445 457
3. F. Fazekas Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group Lancet 349 1997 589 593
4. A. Achiron Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses Neurology 50 1998 398 402
5. P.S. Sorensen Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis Neurology 50 1998 1273 1281
6. M. Lewanska No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment Eur. J. Neurol. 9 2002 565 572
7. J. Haas Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years Mult. Scler. 11 2005 562 567
8. A. Achiron Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis J. Neurol. 251 2004 1133 1137
9. J. Haas, and O.R. Hommes A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis Mult. Scler. 13 2007 900 908
10. F. Fazekas Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial Neurology 71 2008 265 271
11. T. Berger Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics J. Neuroimmunol. 277 2014 145 152
12. C. Galeotti Molecular and immunological biomarkers to predict IVIg response Trends Mol. Med. 21 2015 145 147